Arqule Inc., of Burlington, Mass., said partner Kyowa Hakko Kirin Co. Ltd., of Tokyo, reported top-line results for the JET-HCC phase III trial of tivantinib, a small-molecule c-Met receptor tyrosine kinase inhibitor, in Japan, which did not meet its primary endpoint of progression-free survival.